The result of the MDP 301 announced today was a disappointment for many of us in the New HIV Vaccine and Microbicide Advocacy Society: a coalition that has invested years in working towards gingering public support for New HIV Prevention Technology Research and Development in Nigeria. We had looked forward to the MDP 301 results hoping it will confirm speculations of an effective microbicide following the HPTN 035 results.

 

While the MDP 301 results do show conclusively that 0.5% Pro 2000 does not prevent HIV transmission through vaginal sex, this result have not in anyway diminished the need and importance of microbicide as a possible HIV prevention tool for sexual transmission of HIV infection: the very reason NHVMAS had worked to promote community support for biomedical HIV prevention research.

 

The MDP 301 study is the largest international clinical trial to date and it studied the effectiveness of a preventative HIV gel. Results show no evidence that the vaginal microbicide, PRO 2000, reduces the risk of HIV infection in women as announced by scientists today.

 

This placebo-controlled trial involved 9,385 women at six research centres in four African countries. The study found that the risk of HIV infection in women who were supplied with PRO 2000 gel was not significantly different than in women supplied with placebo gel. Although ineffective in providing protection, PRO 2000 gel itself was safe to use.

 

The report of the trial also shows that trial participants liked the gel and used the gel. Our studies in Nigeria also showed that women engaged in past CS3 and SAVVY trials like the gel. This points to the possibility of women using a gel as a microbicide WHEN a product is finally developed.

 

The results of the MDP 301 study does not reduce in anyway, the need for a product to prevent HIV infection either through anal or vaginal sex. Continuing research into developing a microbicide to be applied topically to prevent sexual transmission of HIV is needed. Development of a product that a woman can control, buy off the counter without prescription, and equally increases sexual pleasure should continue as a research global agenda.

 

We congratulate the MDP team for a successfully conducted trial. We equally appreciate the trial participants, communities and stakeholders in the various countries where these trials were conducted for helping to see to the successful conclusion of this important trial.

 

NHVMAS looks forward to the results of the CAPRISA 004 and the MTN 003 studies that will tell us more about the efficacy of ARV based microbicides. We also look forward to the conduct of future non ARV based microbicide studies while we globally push for universal access for existing and effective HIV prevention tools.